タンズチニブ 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬
説明
Tandutinib is a potent antagonist of platelet-
derived growth factor receptor β (PDGFRβ), FLT3, and c-
Kit (IC
50 = 200, 220, and 170 nM, respectively). It less potently inhibits macrophage colony-
stimulating factor 1 receptor (IC
50 = 3.4 μM) and does not significantly inhibit other tyrosine or serine/threonine kinases. Tandutinib blocks the growth of cells expressing an internal tandem duplication within the juxtamembrane domain of the FLT3 receptor, found in some acute myelogenous leukemia cells. It also impairs the growth of colon cancer cells through its actions on the c-
Kit receptor. Tandutinib reverses multidrug resistance
in vitro by impairing the efflux activity of the multidrug resistance protein 7.
化学的特性
White Solid
使用
An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) and other cancer indications. The drug exhibited limited activity as a single agent in phase I and II clinical trials in patients with AML and myelody
定義
ChEBI: An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a 6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl group, while the hydrogen attached to the nitrogen at position 4
s replaced by a (p-isopropoxyphenyl)aminocarbonyl group. Tandutinib is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT.
タンズチニブ 上流と下流の製品情報
原材料
準備製品